Polycystic kidney disease (PKD) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. Angion Biomedica Corp. 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. Conatus Pharmaceuticals Inc. 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Genzyme Corporation 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. Goldfinch Biopharma Inc 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. IC-MedTech 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. Kadmon Holdings, Inc. 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. ManRos Therapeutics 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Mironid 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. NovaTarg Therapeutics 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. Oarao Therapeutics 6.10.1. Introduction 6.10.2. Financials 6.10.3. Products and Services 6.10.4. SWOT 6.11. Palladio Biosciences 6.11.1. Introduction 6.11.2. Financials 6.11.3. Products and Services 6.11.4. SWOT 6.12. Reata Pharmaceuticals, Inc. 6.12.1. Introduction 6.12.2. Financials 6.12.3. Products and Services 6.12.4. SWOT 6.13. Regulus Therapeutics Inc. 6.13.1. Introduction 6.13.2. Financials 6.13.3. Products and Services 6.13.4. SWOT 6.14. Vertex Pharmaceuticals Incorporated 6.14.1. Introduction 6.14.2. Financials 6.14.3. Products and Services 6.14.4. SWOT 6.15. Xortx Therapeutics Inc. 6.15.1. Introduction 6.15.2. Financials 6.15.3. Products and Services 6.15.4. SWOT